Do we have good surrogate endpoints for survival in breast cancer studies?
Lohrisch
C
C
Investigational Drug Branch for Breast Cancer (IDBBC) Branch of the EORTC, Jules Bordet Institute, Bd de Waterloo 125, 1000 Brussels, Belgium. carolinebrussels@hotmail.com
Piccart
M J
MJ
D001943:Breast Neoplasms / Q000401:mortality* / Q000473:pathology / Q000628:therapy*; D002986:Clinical Trials as Topic; D018450:Disease Progression; D018572:Disease-Free Survival; D005260:Female; D006801:Humans; D008207:Lymphatic Metastasis; D011788:Quality of Life; D016019:Survival Analysis; D015996:Survival Rate; D016896:Treatment Outcome